Treatment | Number of isolates tested | Number able to grow on YMA + antibiotics | % nodule occupancy by marked strain | Competitive ability of marked strain |
---|---|---|---|---|
UCT40a + UCT40aMkd1 | 40 | 30 | 75.0 * | I |
UCT40a + UCT40aMkd2 | 28 | 14 | 50.0 | U |
UCT44b + UCT44bMkd1 | 18 | 4 | 22.2 * | R |
UCT44b + UCT44bMkd2 | 38 | 12 | 31.6 * | R |
UCT44b + UCT44bMkd3 | 26 | 10 | 38.5 | U |
UCT61a + UCT61aMkd1 | 50 | 0 | 0.0 * | R |
UCT61a + UCT61aMkd2 | 52 | 0 | 0.0 * | R |
UCT61a + UCT61aMkd3 | 60 | 0 | 0.0 * | R |
PPRICI3 + PPRICI3Mkd1 | 35 | 21 | 60.0 | U |
PPRICI3 + PPRICI3Mkd2 | 31 | 19 | 61.2 | U |
PPRICI3 + PPRICI3Mkd3 | 31 | 10 | 32.3 | U |